Roche Broadens Cervical Cancer Testing Lineup With MTM Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Roche will seek PMA approval for MTM Laboratories’ cervical cancer tests following acquisition of the diagnostics firm for up to $270 million in a deal announced July 19.